medigraphic.com
ISSN 2078-7170 (Electronic)

2019, Number 1

<< Back Next >>

CorSalud 2019; 11 (1)

The leucoglycaemic index is a predictor of one-year all-cause mortality in Cuban patients with ST-segment elevation acute myocardial infarction

Padilla-Cueto D, Hernández-Negrín H, Ramírez-Gómez JI, Pérez-Valdivia A, Cárdenas-Sánchez AL, Alfonso-Izquierdo A

Language: Spanish
References: 32
Page: 21-29
PDF size: 895.33 Kb.


ABSTRACT

Introduction: The leuko-glycaemic index has been proposed as a prognostic marker of death in patients with acute myocardial infarction, but there is uncertainty surrounding its prognostic value to predict one-year mortality.
Objectives: The aim of this study was to determine the prognostic value of leukoglycaemic index for one-year mortality in Cuban patients with ST-segment elevation myocardial infarction.
Method: The data were obtained from the medical records and all cause one-year deaths was the primary endpoint. The leuko-glycaemic index was calculated from measurements at admission. The patients were divided into leuko-glycaemic index tertiles to be evaluated. Receiver operating characteristics and Kaplan-Meier survival curves were performed. Cox regression model was used for all multivariable analysis.
Results: Three hundred and forty-four patients were assessed (median age, 68 years; 65.7% males; 25.6% diabetic). The mortality rate was 25.6%, being significantly higher in the upper tertile (55.7%, p<0.0001). The deceased patients presented a median of leuko-glycaemic index significantly higher than the survivors (2.18 and 1.34 respectively, p<0.0001). The area under the curve for leuko-glycaemic index was 0.715 and its cut-off value was 2.2. Any leuko-glycaemic index value higher than 2.2 was associated with significantly lower survival (177 vs. 309 days, p<0.0001) and it was an independent predictor of mortality (HR=3.56, CI 95%, 2.09- 6.07, p<0.0001).
Conclusions: The leuko-glycaemic index is a good predictor for all cause one-year mortality in patients with ST-segment elevation myocardial infarction.


REFERENCES

  1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.

  2. Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2017;14(3):133-44.

  3. Eisen A, Giugliano RP, Braunwald E. Updates on acute coronary syndrome: A review. JAMA Cardiol. 2016;1(6):718-30.

  4. Dimitrijevic O, Stojcevski BD, Ignjatovic S, Singh NM. Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. Int Heart J. 2006;47(6):833-42.

  5. Prondzinsky R, Unverzagt S, Lemm H, Wegener NA, Schlitt A, Heinroth KM, et al. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol. 2012;101(5):375-84.

  6. Núñez J, Fácila L, Llàcer À, Sanchís J, Bodí V, Bertomeu V, et al. Valor pronóstico del recuento leucocitario en el infarto agudo de miocardio: mortalidad a largo plazo. Rev Esp Cardiol. 2005;58(6):631-9.

  7. Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb Haemost. 2011;106(4):591-9.

  8. Angeli F, Reboldi G, Poltronieri C, Lazzari L, Sordi M, Garofoli M, et al. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. Ther Adv Cardiovasc Dis. 2015;9(6):412-24.

  9. Eitel I, Hintze S, de Waha S, Fuernau G, Lurz P, Desch S, et al. Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction: insights from contrast-enhanced magnetic resonance imaging. Circ Cardiovasc Imaging. 2012;5(6):708-18.

  10. Quiroga W, Conci E, Zelaya F, Isa M, Pacheco G, Sala J, et al. Estratificación del riesgo en el infarto agudo de miocardio según el índice leucoglucémico. ¿El Killip-Kimball de laboratorio? Rev Fed Arg Cardiol. 2010;39(1):29-34.

  11. León-Aliz E, Moreno-Martínez FL, Pérez-Fernández GA, Vega-Fleites LF, Rabassa-López-Calleja MA. Índice leuco-glucémico como marcador pronóstico de la evolución intrahospitalaria en pacientes con infarto agudo de miocardio con elevación del ST. Clin Investig Arterioscler. 2014;26(4):168-75.

  12. Hirschson Prado A, Higa C, Merlo P, Domine E, Blanco P, Vázquez GA, et al. Valor pronóstico del índice leucoglucémico en el infarto agudo de miocardio. Resultados del Registro Multicéntrico SCAR. Rev Argent Cardiol. 2014;82(6):500-5.

  13. Díaz Benítez RE, Correa Morales AM, Reyes Hernández LM, Carvajal Sánchez PA, Coronado Herrera Y, González Rivera EM. Hemoglobina glucosilada e índice leucoglucémico como determinaciones pronósticas en el síndrome coronario agudo. CorSalud [Internet]. 2016 [citado 18 Jul 2018];8(3):153-63. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/135/321

  14. Dragu R, Khoury S, Zuckerman R, Suleiman M, Mutlak D, Agmon Y, et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis. 2008;196(1):405-12.

  15. Arbel Y, Shacham Y, Ziv-Baran T, Laufer Perl M, Finkelstein A, Halkin A, et al. Higher neutrophil/lymphocyte ratio is related to lower ejection fraction and higher long-term all-cause mortality in ST-elevation myocardial infarction patients. Can J Cardiol. 2014;30(10):1177-82.

  16. Núñez J, Núñez E, Bodí V, Sanchis J, Miñana G, Mainar L, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol. 2008;101(6):747-52.

  17. Cho KI, Ann SH, Singh GB, Her AY, Shin E. Combined usefulness of the platelet-to-lymphocyte ratio and the neutrophil-to-lymphocyte ratio in predicting the long-term adverse events in patients who have undergone percutaneous coronary intervention with a drug-eluting stent. PloS One [Internet]. 2015 [citado 15 Jul 2018];10(7):e0133934. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133934

  18. Ayça B, Akin F, Celik O, Sahin I, Yildiz SS, Avci II, et al. Neutrophil to lymphocyte ratio is related to stent thrombosis and high mortality in patients with acute myocardial infarction. Angiology. 2015;66(6):545-52.

  19. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653-7.

  20. Zhou D, Wan Z, Fan Y, Zhou J, Yuan Z. A combination of the neutrophil-to-lymphocyte ratio and the GRACE risk score better predicts PCI outcomes in Chinese Han patients with acute coronary syndrome. Anatol J Cardiol. 2015;15(12):995-1001.

  21. Sen N, Afsar B, Ozcan F, Buyukkaya E, Isleyen A, Akcay AB, et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis. 2013;228(1):203-10.

  22. Kounis NG, Soufras GD, Tsigkas G, Hahalis G. White blood cell counts, leukocyte ratios, and eosinophils as inflammatory markers in patients with coronary artery disease. Clin Appl Thromb Hemost. 2015;21(2):139-43.

  23. Pluskota E, Woody NM, Szpak D, Ballantyne CM, Soloviev DA, Simon DI, et al. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood. 2008;112(6):2327-35.

  24. Arruda-Olson AM, Reeder GS, Bell MR, Weston SA, Roger VL. Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study. Circ Cardiovasc Qual Outcomes. 2009;2(6):656-62.

  25. Deckers JW, van Domburg RT, Akkerhuis M, Nauta ST. Relation of admission glucose levels, short- and long-term (20-year) mortality after acute myocardial infarction. Am J Cardiol. 2013;112(9):1306-10.

  26. Planer D, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Xu K, et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol. 2013;167(6):2572-9.

  27. Monteiro S, Monteiro P, Gonçalves F, Freitas M, Providência LA. Hyperglycaemia at admission in acute coronary syndrome patients: prognostic value in diabetics and non-diabetics. Eur J Cardiovasc Prev Rehabil. 2010;17(2):155-9.

  28. Ladeira RT, Baracioli LM, Faulin TE, Abdalla DS, Seydell TM, Maranhão RC, et al. Unrecognized diabetes and myocardial necrosis: predictors of hyperglycemia in myocardial infarction. Arq Bras Cardiol. 2013;100(5):404-11.

  29. Naber CK, Mehta RH, Jünger C, Zeymer U, Wienbergen H, Sabin GV, et al. Impact of admission blood glucose on outcomes of nondiabetic patients with acute ST-elevation myocardial infarction (from the German Acute Coronary Syndromes [ACOS] Registry). Am J Cardiol. 2009;103(5):583-7.

  30. Koraćević G, Vasiljević S, Velicković-Radovanović R, Sakac D, Obradović S, Damjanović M, et al. Stress hyperglycemia in acute myocardial infarction. Vojnosanit Pregl. 2014;71(9):858-69.

  31. Puig Domingo M. Función plaquetaria e hiperglucemia en el síndrome coronario. Rev Esp Cardiol. 2014;67(1):3-5.

  32. Seoane LA, Korolov Y, Vrancic M, Camporrotondo M, Piccinini F, Hirschson Prado A, et al. Valor pronóstico del índice leucoglucémico en el postoperatorio de cirugía cardíaca. Cir Cardiov. 2017;24(6):335-9.




2020     |     www.medigraphic.com